Acticor Biotech Stock Quote ALACT - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.60

Bid

0.60

Ask

0.65

Volume

11,981

0.60 Day's Range 0.66

0.27 52 Week Range 6.00

Market Cap

10.241M

Previous Close

0.65

Open

0.66

Last Trade

0.6

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

131,343

Shares Outstanding

15,755,227

Dividend Yield

PE Ratio

-0.60

Earnings Per Share (EPS)

-1.01

Revenue

2.7M

Net Profit

-15.88M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.acticor-biotech.com

Headquarters

Paris, Paris, Fra

Founded

1970

Acticor Biotech is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALACT. The last closing price for Acticor Biotech was 0.65 €. Over the last year, Acticor Biotech shares have traded in a share price range of 0.27 € to 6.00 €.

Acticor Biotech currently has 15,755,227 shares outstanding. The market capitalization of Acticor Biotech is 10.24 € million. Acticor Biotech has a price to earnings ratio (PE ratio) of -0.60.

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of May 31, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...

Acticor Biotech fait le point sur le plan de développement clinique du glenzocimab dans le traitement des urgences cardio-vasculaires

Nouvelles analyses de l’étude de phase 2/3 ACTISAVE démontrant des tendances favorables pour le glenzocimab sur des sous-populations de patients Poursuite des études cliniques : GREEN de phase...

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies New analyses of ACTISAVE phase 2/3 study show positive trends for...

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...

ACTICOR BIOTECH : Présentation des principaux résultats de l’étude de phase 2/3 ACTISAVE dans le traitement de l’AVC lors de l’ESOC 2024

Des données sur des sous-groupes spécifiques ouvrent la voie à de nouvelles perspectives Poursuite réaffirmée de la conduite des études de phase 2/3 GREEN et de phase 2b LIBERATE Regulatory...

ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of glenzocimab, an innovative drug for the treatment of cardiovascular...

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment

Analysis of the primary and secondary endpoints of the phase 2/3 ACTISAVE study showed no improved efficacy with glenzocimab Key results from this study will be presented at ESOC on May 15...

Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

Results of ACTISAVE phase 2/3 clinical study in stroke expected in Q2 2024 Presentation of results during ESOC from 15 to 17 May 2024 Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 –...

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first...

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.11	-15.4929577465	0.71	0.71	0.6	7058	0.6742237	DE
4	-0.388	-39.2712550607	0.988	0.99	0.6	17732	0.74091545	DE
12	-3.04	-83.5164835165	3.64	4.21	0.27	131343	0.7157173	DE
26	-2.38	-79.8657718121	2.98	5.32	0.27	72426	1.20785341	DE
52	-4.84	-88.9705882353	5.44	6	0.27	37173	1.31350795	DE
156	-6.5	-91.5492957746	7.1	11	0.27	15804	2.06638517	DE
260	0.35	140	0.25	11	0.11	66082	1.20165068	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BENFBeneficient	$ 4.515 (110.00%)	38.84M
QLGNQualigen Therapeutics Inc	$ 0.2746 (56.56%)	233.99M
INVZWInnoviz Technologies Ltd	$ 0.2499 (51.91%)	17.79k
MAXNMaxeon Solar Technologies Ltd	$ 0.2436 (40.32%)	330.34M
XHGXChange TED Inc	$ 1.1598 (39.73%)	63.9M
VEVVicinity Motor Corporation	$ 0.3878 (-31.24%)	310.8k
SKYESkye Bioscience Inc	$ 5.57 (-25.34%)	222.14k
SPWRSunPower Corporation	$ 2.09 (-22.01%)	14.11M
CYNCYNGN Inc	$ 4.1897 (-21.98%)	292.27k
JZXNJiuzi Holdings Inc	$ 2.77 (-18.53%)	38.07k
MAXNMaxeon Solar Technologies Ltd	$ 0.2436 (40.32%)	330.34M
QLGNQualigen Therapeutics Inc	$ 0.2746 (56.56%)	233.99M
NVDANVIDIA Corporation	$ 127.5005 (-0.61%)	148.84M
TSLATesla Inc	$ 248.74 (0.95%)	114.16M
SQQQProShares UltraPro Short QQQ	$ 7.47 (-2.86%)	92.35M